Judge rejects P&G, Sanofi arguments against Boniva marketing
Pharma Compliance Alert, September 12, 2006
A federal judge last week rejected an argument from Procter & Gamble and Sanofi Aventis claiming that Roche and GlaxoSmithKline's advertising for the osteoporosis drug Boniva is misleading. P&G and Sanofi Aventis, which co-market the osteoporosis drug Actonel, filed a suit saying that ads for Boniva falsely imply that the drug is as effective as Actonel at preventing nonspinal fractures. The suit argued that the Boniva label does not support these claims and requested a halt on the ads.
However, the judge rejected the claims, writing that "there is no doubt that Boniva is a safe and effective drug which the FDA has approved for the treatment and prevention of osteoporosis in postmenopausal women, without limitation as to vertebral and nonvertebral sites.nor is Actonel superior to Boniva."
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- Capturing all necessary codes for IUD insertion and removal can be challenging
- QA:Coding multiple initial infusions
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Q&A tackles coding questions about injections and infusions
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- Case Management Monthly, June 2012
- Searched